Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - abacavir sulfate,lamivudine -

United States - English - NLM (National Library of Medicine)

viiv healthcare company - lamivudine (unii: 2t8q726o95) (lamivudine - unii:2t8q726o95) - lamivudine 150 mg - epivir is a nucleoside analogue indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (hiv‑1) infection. limitations of use: epivir is contraindicated in patients with a previous hypersensitivity reaction to lamivudine. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to epivir during pregnancy. healthcare providers are encouraged to register patients by calling the antiretroviral pregnancy registry (apr) at 1-800-258-4263. risk summary available data from the apr show no difference in the overall risk of birth defects for lamivudine compared with the background rate for birth defects of 2.7% in the metropolitan atlanta congenital defects program (macdp) reference population (see data) . the apr uses the macdp as the u.s. reference population for birth defects in the general population. the macdp evaluates women and infants from a limited geographic area and does not include outcome

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - lamivudine, quantity: 300 mg; abacavir hydrochloride monohydrate, quantity: 714.162 mg (equivalent: abacavir, qty 600 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; crospovidone; povidone; magnesium stearate; ferric oxide; titanium dioxide; hypromellose; sunset yellow fcf; polysorbate 80; macrogol 400 - abacavir/lamivudine lapl is a combination of two nucleoside analogues (abacavir and lamivudine). abacavir/lamivudine lapl is indicated in antiretroviral combination therapy for the treatment of human immunodeficiency virus (hiv) infection in adults and adolescents from 12 years of age.

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - lamivudine, quantity: 300 mg; abacavir hydrochloride monohydrate, quantity: 714.162 mg (equivalent: abacavir, qty 600 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; crospovidone; povidone; magnesium stearate; ferric oxide; titanium dioxide; hypromellose; sunset yellow fcf; polysorbate 80; macrogol 400 - abacavir/lamivudine lapl is a combination of two nucleoside analogues (abacavir and lamivudine). abacavir/lamivudine lapl is indicated in antiretroviral combination therapy for the treatment of human immunodeficiency virus (hiv) infection in adults and adolescents from 12 years of age.

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - lamivudine, quantity: 300 mg; abacavir hydrochloride monohydrate, quantity: 714.162 mg (equivalent: abacavir, qty 600 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; crospovidone; povidone; magnesium stearate; ferric oxide; titanium dioxide; hypromellose; sunset yellow fcf; polysorbate 80; macrogol 400 - abacavir/lamivudine lupin is a combination of two nucleoside analogues (abacavir and lamivudine). abacavir/lamivudine lupin is indicated in antiretroviral combination therapy for the treatment of human immunodeficiency virus (hiv) infection in adults and adolescents from 12 years of age.

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - lamivudine, quantity: 300 mg; abacavir hydrochloride monohydrate, quantity: 714.162 mg (equivalent: abacavir, qty 600 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; crospovidone; povidone; magnesium stearate; ferric oxide; titanium dioxide; hypromellose; sunset yellow fcf; polysorbate 80; macrogol 400 - abacavir/lamivudine lupin is a combination of two nucleoside analogues (abacavir and lamivudine). abacavir/lamivudine lupin is indicated in antiretroviral combination therapy for the treatment of human immunodeficiency virus (hiv) infection in adults and adolescents from 12 years of age.

United States - English - NLM (National Library of Medicine)

glaxosmithkline llc - lamivudine (unii: 2t8q726o95) (lamivudine - unii:2t8q726o95) - lamivudine 100 mg - epivir-hbv is indicated for the treatment of chronic hepatitis b virus (hbv) infection associated with evidence of hepatitis b viral replication and active liver inflammation [see clinical studies (14.1, 14.2)]. the following points should be considered when initiating therapy with epivir-hbv: epivir-hbv is contraindicated in patients with a previous hypersensitivity reaction to lamivudine. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to lamivudine during pregnancy. healthcare providers are encouraged to register patients by calling the antiretroviral pregnancy registry (apr) at 1-800-258-4263. risk summary available data from the apr show no substantial difference in the risk of overall major birth defects for lamivudine compared with the background rate for major birth defects of 2.7% reported in the u.s. reference population of the metropolitan atlanta congenital defects program (macdp). the apr uses the macdp as a u.s. reference popul

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - lamivudine -

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - lamivudine -

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - lamivudine,zidovudine -